University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Valenyx Therapeutics

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

Oncology

Therapeutic Indications

Non-small cell lung cancerSolid tumors

Funding Stage

Seed

Founders

Md KabirJian JinYi Shi

Website

https://www.valenyxtx.com

Valenyx Therapeutics is developing multispecific nanobody-based biologics for complex diseases, starting with osimertinib-resistant non-small cell lung cancer. Its platform combines proteomics-based discovery of serum-matured nanobodies with machine-learning candidate ranking and epitope-first engineering. [1]

The modular nanobody formats can be assembled into degrader-drug conjugates, T-cell engagers, antibody-oligonucleotide conjugates, and brain-shuttle biologics. The lead program, VT-001, is a tri-specific degrader-drug conjugate for non-small cell lung cancer and other solid tumors and is in IND-enabling studies. VT-002, a tri-specific dual-degrader conjugate, is in preclinical development, and VT-003, a broad-tissue single-domain antibody for CNS and muscle disease, is in discovery. [1]

The company is based in New York and is co-founded by CEO Md Kabir and scientific co-founders Jian Jin and Yi Shi, whose research on multispecific nanobody degraders underpins the platform. [2]

Discover More with AI